Please login to the form below

Not currently logged in
Email:
Password:

Nycomed to build plant in Russia

Swiss company invests in production facility

Nycomed has announced plans to build a state-of-the-art pharmaceutical plant near the Russian city of Yaroslavl. Construction on the facility, which will manufacture medicines for Commonwealth of Independent States (CIS) countries, starts in 2010 and production is scheduled to begin in 2014. 

Sergey Vakhrukov, Governor of Yaroslavl commented: "Personally, I am delighted that Nycomed is investing in our region and we are looking forward to continuing the great cooperation we have established."

Markets in the CIS contribute 10 per cent to the Swiss-based pharma company's turnover and play an important role in its growth strategy. Nycomed is to invest between €65m and €75m in the venture and will employ about 150 people.

Jostein Davidsen, senior vice president, Nycomed Group, and president Nycomed Russia-CIS said: "We have inspected many possible locations in many different regions…A key factor for our decision was the long-term availability of a qualified workforce [this is] where the medical academy in Yaroslavl plays an important role."

Nycomed's portfolio is focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. It also has a range of OTC products.

22nd September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics